Zydus strengthens its derma portfolio with the brand acquisition of Melgain

8 August 2016

India’s Zydus Group has acquired the dermatology brand Melgain from Hyderabad-based Issar Pharma.

In India, Melgain will be marketed by Liva Healthcare, a specialty division of the group catering to the dermatological segment. Zydus also has an option to launch this product in other global markets where it is not available. Financial terms of the transaction were not disclosed.

Melgain is used for the treatment of vitiligo, a chronic skin condition characterized by portions of the skin losing their pigment. It occurs when skin pigment cells die or are unable to function. Though the reason for the onset of the condition is not known, the most widely accepted view is that the depigmentation occurs because vitiligo is an autoimmune disease - a disease in which a person's immune system reacts against the body's own organs or tissues.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK